Harbour Antibodies Licenses H2L2 Mice to Pfizer

  Harbour Antibodies Licenses H2L2 Mice to Pfizer

Business Wire

ROTTERDAM, the Netherlands & CAMBRIDGE, Mass. -- July 24, 2013

Harbour Antibodies, the creator of transgenic mice to aid in the development
of new human therapeutic antibodies, announced today that it has licensed its
H2L2 mice, which can generate human monoclonal antibodies, to Pfizer Inc.

Harbour Antibodies’ transgenic H2L2 mice enable biotechs, pharmaceutical
companies and academic research labs to speed new drug development by
generating human antibodies using traditional hybridoma technology. Under the
licensing agreement, Pfizer will have the option to use the mice in as many
projects as they wish without disclosing the nature of the projects to
Harbour.

This licensing deal marks the third partnership for Harbour Antibodies.
Previous deals have been announced involving the H2L2 mice with Eli Lilly and
Company and ChemPartner Co.

About Harbour Antibodies.
Harbour Antibodies is enabling the development of new therapeutic human
monoclonal antibodies through the creation of two lines of transgenic mice.
These are the H2L2 mice, which generate full IgG and the HCAb mice, which
generate heavy chain only human antibodies. Both lines are currently available
for licensing. For more information, please visitwww.harbourantibodies.com.

Contact:

Harbour Antibodies
BJ Bormann, PhD, +1 617-203-2182 Ext 1
CEO
bj@harbourantibodies.com
 
Press spacebar to pause and continue. Press esc to stop.